These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8640540)

  • 1. Nonstop treatment of cystic fibrosis.
    Dietz HC; Hamosh A
    Nat Med; 1996 Jun; 2(6):608-9. PubMed ID: 8640540
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?
    Lallemand JY; Stoven V; Annereau JP; Boucher J; Blanquet S; Barthe J; Lenoir G
    Lancet; 1997 Sep; 350(9079):711-2. PubMed ID: 9291908
    [No Abstract]   [Full Text] [Related]  

  • 3. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
    Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 5. Lung clearance index response in patients with CF with class III CFTR mutations.
    Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
    Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combating cystic fibrosis: in search for CF transmembrane conductance regulator (CFTR) modulators.
    Noy E; Senderowitz H
    ChemMedChem; 2011 Feb; 6(2):243-51. PubMed ID: 21275046
    [No Abstract]   [Full Text] [Related]  

  • 8. [Protein repair therapy in cystic fibrosis].
    Clément A; Tamalet A; Fauroux B; Epaud R
    Rev Prat; 2003 Jan; 53(2):163-6. PubMed ID: 12664848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 10. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 14. [New therapeutic approaches in cystic fibrosis].
    Vestner A; Schrepfer B; Kockler J; Mohr F; Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2008; 37(5):354-5. PubMed ID: 18729285
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel pharmacologic therapies for cystic fibrosis.
    Zeitlin PL
    J Clin Invest; 1999 Feb; 103(4):447-52. PubMed ID: 10021451
    [No Abstract]   [Full Text] [Related]  

  • 16. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 17. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
    Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.